Skip to content
Research Article Open access CC BY 4.0

The Action of Adrenergic Agonists and Antagonists in the Present of Bupropion in the Vta Nucleus on Morphine Withdrawal Syndrome on Episodic Behaviors in Rats

Farzad Moradpour, Samad Zare, Firouz Ghaderi Pakdel

Asian Journal of Biology · pp. 19–27 · Published 15 Feb 2022

10.9734/ajob/2022/v14i230209

Abstract

Bupropion is a unique and non-nicotine smoke cessation agent, and it is using smoke cessation drugs under FDA approval despite its antidepressant effect. In the current study, we considered the short-term interaction of bupropion, adrenoceptors proprietary agonists and antagonists (phenylephrine, prazosin, clonidine and yohimbine) in intra VTA injection on naloxone precipitated withdrawal symptoms. The injection guide cannulae were implanted into VTA nuclei according to stereotaxic surgery under sterile conditions. The sham group was received saline as a drug vehicle, but treated groups received 2.5 mg/μl/min of bupropion alone and with doses of phenylephrine (0.2 µg/µl/minute), prazosin (1 µg/µl/minute), clonidine and yohimbine (2 µg/µl/minute) 20 before bupropion. Dependent and non-dependent control groups had surgery, but they had no intra-VTA injection. In each treatment group, 8 rats were used. Withdrawal signs were precipitated by naloxone (1.2 mg/Kg, s.c.), observed continuously and registered online each minute. The behaviors captured by 3 digital cameras indifferent view (30 min) for offline analysis. Signs were counted and analyzed within and between groups. The results showed that intra-VTA bupropion can alter the occurrence of withdrawal symptoms and decrease more of them. Adrenoceptor agonists decrease some of the symptoms. This decrease was significant statistically in comparison with sham and control groups and between treatment groups. Occurrence extents of withdrawal symptoms have no significance statistically in naive control and sham groups toward the witness group. Results showed adrenergic system has a role in the opioid system and drug dependence; also between influences extent of adrenoceptor's species is a difference in accession of diverse withdrawal signs.

Bupropion clonidine morphine dependence naloxone phenylephrine prazosin withdrawal syndrome yohimbine ventral tegmental area

References (17)

  1. 1 The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat [DOI]
  2. 2 The Neuroscience of Natural Rewards: Relevance to Addictive Drugs [DOI]
  3. 3 Molecular mechanisms of drug addiction [DOI]
  4. 4 Bupropion Is a Nicotinic Antagonist [DOI]
  5. 5 Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release [DOI]
  6. 6 A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor [DOI]
  7. 7 Locus coeruleus and regulation of behavioral flexibility and attention [DOI]
  8. 8 Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent [DOI]
  9. 9 Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats [DOI]
  10. 10 Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area [DOI]
  11. 11 Involvement of dopamine D2 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat [DOI]
  12. 12 Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor [DOI]
  13. 13 Bupropion attenuates methamphetamine self-administration in adult male rats [DOI]
  14. 14 Addictive Drugs and Brain Stimulation Reward [DOI]
  15. 15 Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion [DOI]
  16. 16 Protective effect of bupropion on morphine tolerance and dependence in mice [DOI]
  17. 17 Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

20

Page views

0

PDF downloads

2

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.